Rhabdoid Tumor Predisposition Syndrome : A Comprehensive Review of Genetics, Clinical Manifestations, and Management

Rhabdoid tumor predisposition syndrome (RTPS) is a rare autosomal dominant disorder characterized by an increased risk of developing malignant rhabdoid tumors in early childhood. This syndrome is primarily caused by germline heterozygous loss-of-function pathogenic variants in the SMARCB1 gene (RTPS...

Full description

Saved in:
Bibliographic Details
Published inJournal of Korean Neurosurgical Society Vol. 68; no. 3; pp. 311 - 320
Main Authors Kim, Taehoon, Phi, Ji Hoon
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Neurosurgical Society 01.05.2025
대한신경외과학회
Subjects
Review
신경외과학
Rhabdoid tumor predisposition syndrome
Epigenomics
Online AccessGet full text
ISSN2005-3711
1598-7876
DOI10.3340/jkns.2025.0014

Cover

Abstract Rhabdoid tumor predisposition syndrome (RTPS) is a rare autosomal dominant disorder characterized by an increased risk of developing malignant rhabdoid tumors in early childhood. This syndrome is primarily caused by germline heterozygous loss-of-function pathogenic variants in the SMARCB1 gene (RTPS1) and rarely in the SMARCA4 gene (RTPS2). RTPS is characterized by the development of atypical teratoid rhabdoid tumors of the central nervous system, malignant rhabdoid tumors of the kidney, and/or extrarenal extracranial rhabdoid tumors. The syndrome demonstrates high penetrance, with most tumors developing before age 3 years, and carries a poor prognosis despite intensive multimodal therapy. Early diagnosis through genetic testing, implementation of surveillance protocols, and aggressive treatment approaches are crucial for improving outcomes. This review comprehensively examines the genetic basis, clinical manifestations, surveillance strategies, and current management approaches for RTPS, with particular emphasis on emerging therapeutic options and the importance of multidisciplinary care.
AbstractList Rhabdoid tumor predisposition syndrome (RTPS) is a rare autosomal dominant disorder characterized by an increased risk of developing malignant rhabdoid tumors in early childhood. This syndrome is primarily caused by germline heterozygous loss-of-function pathogenic variants in the SMARCB1 gene (RTPS1) and rarely in the SMARCA4 gene (RTPS2). RTPS is characterized by the development of atypical teratoid rhabdoid tumors of the central nervous system, malignant rhabdoid tumors of the kidney, and/or extrarenal extracranial rhabdoid tumors. The syndrome demonstrates high penetrance, with most tumors developing before age 3 years, and carries a poor prognosis despite intensive multimodal therapy. Early diagnosis through genetic testing, implementation of surveillance protocols, and aggressive treatment approaches are crucial for improving outcomes. This review comprehensively examines the genetic basis, clinical manifestations, surveillance strategies, and current management approaches for RTPS, with particular emphasis on emerging therapeutic options and the importance of multidisciplinary care.
Rhabdoid tumor predisposition syndrome (RTPS) is a rare autosomal dominant disorder characterized by an increased risk of developing malignant rhabdoid tumors in early childhood. This syndrome is primarily caused by germline heterozygous loss-of-function pathogenic variants in the SMARCB1 gene (RTPS1) and rarely in the SMARCA4 gene (RTPS2). RTPS is characterized by the development of atypical teratoid rhabdoid tumors (ATRT) of the central nervous system, malignant rhabdoid tumors of the kidney (RTK), and/or extrarenal extracranial rhabdoid tumors (EERT). The syndrome demonstrates high penetrance, with most tumors developing before age 3 years, and carries a poor prognosis despite intensive multimodal therapy. Early diagnosis through genetic testing, implementation of surveillance protocols, and aggressive treatment approaches are crucial for improving outcomes. This review comprehensively examines the genetic basis, clinical manifestations, surveillance strategies, and current management approaches for RTPS, with particular emphasis on emerging therapeutic options and the importance of multidisciplinary care.Rhabdoid tumor predisposition syndrome (RTPS) is a rare autosomal dominant disorder characterized by an increased risk of developing malignant rhabdoid tumors in early childhood. This syndrome is primarily caused by germline heterozygous loss-of-function pathogenic variants in the SMARCB1 gene (RTPS1) and rarely in the SMARCA4 gene (RTPS2). RTPS is characterized by the development of atypical teratoid rhabdoid tumors (ATRT) of the central nervous system, malignant rhabdoid tumors of the kidney (RTK), and/or extrarenal extracranial rhabdoid tumors (EERT). The syndrome demonstrates high penetrance, with most tumors developing before age 3 years, and carries a poor prognosis despite intensive multimodal therapy. Early diagnosis through genetic testing, implementation of surveillance protocols, and aggressive treatment approaches are crucial for improving outcomes. This review comprehensively examines the genetic basis, clinical manifestations, surveillance strategies, and current management approaches for RTPS, with particular emphasis on emerging therapeutic options and the importance of multidisciplinary care.
Rhabdoid tumor predisposition syndrome (RTPS) is a rare autosomal dominant disorder characterized by an increased risk of developing malignant rhabdoid tumors in early childhood. This syndrome is primarily caused by germline heterozygous loss-of-function pathogenic variants in the SMARCB1 gene (RTPS1) and rarely in the SMARCA4 gene (RTPS2). RTPS is characterized by the development of atypical teratoid rhabdoid tumors of the central nervous system, malignant rhabdoid tumors of the kidney, and/or extrarenal extracranial rhabdoid tumors. The syndrome demonstrates high penetrance, with most tumors developing before age 3 years, and carries a poor prognosis despite intensive multimodal therapy. Early diagnosis through genetic testing, implementation of surveillance protocols, and aggressive treatment approaches are crucial for improving outcomes. This review comprehensively examines the genetic basis, clinical manifestations, surveillance strategies, and current management approaches for RTPS, with particular emphasis on emerging therapeutic options and the importance of multidisciplinary care. KCI Citation Count: 0
Rhabdoid tumor predisposition syndrome (RTPS) is a rare autosomal dominant disorder characterized by an increased risk of developing malignant rhabdoid tumors in early childhood. This syndrome is primarily caused by germline heterozygous loss-of-function pathogenic variants in the SMARCB1 gene (RTPS1) and rarely in the SMARCA4 gene (RTPS2). RTPS is characterized by the development of atypical teratoid rhabdoid tumors of the central nervous system, malignant rhabdoid tumors of the kidney, and/or extrarenal extracranial rhabdoid tumors. The syndrome demonstrates high penetrance, with most tumors developing before age 3 years, and carries a poor prognosis despite intensive multimodal therapy. Early diagnosis through genetic testing, implementation of surveillance protocols, and aggressive treatment approaches are crucial for improving outcomes. This review comprehensively examines the genetic basis, clinical manifestations, surveillance strategies, and current management approaches for RTPS, with particular emphasis on emerging therapeutic options and the importance of multidisciplinary care.
Author Phi, Ji Hoon
Kim, Taehoon
Author_xml – sequence: 1
  givenname: Taehoon
  orcidid: 0000-0001-7157-2119
  surname: Kim
  fullname: Kim, Taehoon
– sequence: 2
  givenname: Ji Hoon
  orcidid: 0000-0002-9603-5843
  surname: Phi
  fullname: Phi, Ji Hoon
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40143702$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003197979$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNpVkcFv0zAUhy00xLrBlSPyESFSnu0kdrigqoIxaROolLPl2M7qNbE7Oy3af4-zjmnIhye99_l7tn5n6MQHbxF6S2DOWAmfbrc-zSnQag5AyhdoRqpGFFzw-gTNKEBVME7IKTpL6RagZiCqV-i0zCzjQGdoXG1Ua4IzeL0fQsQ_ozUu7UJyowse_7r3JobB4s94gZdh2EW7sT65g8Ure3D2Dw4dvrDejk6nj3jZO--06vG18q6zaVSTJQ-UN1NP3djB-vE1etmpPtk3j_Uc_f72db38Xlz9uLhcLq4KzQQbi07XVLWlNkbrlgPjqiSNIFCWgmugQlesrRra8NZYYAKIqo2pa2hF1bW5w87Rh6PXx05utZNBuYd6E-Q2ysVqfSkJcOC84hn-coR3-3awRud3RtXLXXSDivcPV_-feLfJooMkFGpa0Tob3j8aYrjb59_LwSVt-155G_ZJMiKmI0iT0XfPlz1t-RdMBuZHQMeQUrTdE0JATsnLKXk5JS-n5NlfCLqiHg
Cites_doi 10.1038/s41467-020-18070-y
10.1093/neuonc/noy111
10.1053/j.semdp.2020.05.005
10.1016/j.celrep.2019.10.013
10.2350/14-07-1531-misc.1
10.1016/j.gore.2015.02.002
10.1093/neuonc/noz235
10.1080/14728222.2018.1451839
10.1177/1093526617749671
10.1016/j.wneu.2017.11.158
10.1002/pbc.30979
10.1111/j.1440-1827.2006.01962.x
10.1007/s00431-010-1377-2
10.1007/s00401-018-1814-2
10.1093/noajnl/vdae158
10.1086/302639
10.1016/j.bcp.2023.115727
10.1038/ng.3958
10.1158/1078-0432.ccr-17-0834
10.1002/pbc.22922
10.1016/s1470-2045(13)70088-3
10.1053/j.semdp.2021.03.003
10.1007/s10689-015-9836-6
10.1002/pbc.25093
10.1055/s-0036-1579756
10.1002/pbc.24793
10.1615/critrevoncog.2015013566
10.1016/j.ejca.2020.10.004
10.1093/neuonc/noz244
10.1038/ng.2628
10.1634/theoncologist.2018-0416
10.1200/jco.19.01776
10.1038/ng.3746
10.1155/2013/315170
10.1038/s41431-018-0143-1
10.1038/28212
10.1016/j.ajhg.2010.01.013
10.1007/s00401-020-02250-7
10.1002/pbc.22831
10.1097/pas.0b013e3182196a39
10.3390/cancers14092185
10.1007/s10689-021-00229-1
10.2147/cmar.s289544
10.1158/1078-0432.ccr-17-0595
10.1158/1078-0432.ccr-10-1795
10.1016/j.ccell.2019.10.008
ContentType Journal Article
Copyright Copyright © 2025 The Korean Neurosurgical Society 2025
Copyright_xml – notice: Copyright © 2025 The Korean Neurosurgical Society 2025
DBID AAYXX
CITATION
NPM
7X8
5PM
ACYCR
DOI 10.3340/jkns.2025.0014
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1598-7876
EndPage 320
ExternalDocumentID oai_kci_go_kr_ARTI_10707757
PMC12062526
40143702
10_3340_jkns_2025_0014
Genre Journal Article
GroupedDBID ---
29K
2WC
5-W
53G
5GY
8JR
8XY
9ZL
AAYXX
ABDBF
ACUHS
AENEX
ALMA_UNASSIGNED_HOLDINGS
CITATION
CS3
D-I
DIK
E3Z
EBD
EF.
F5P
FRP
GROUPED_DOAJ
HYE
OK1
RPM
W2D
KVFHK
NPM
7X8
5PM
ACYCR
ID FETCH-LOGICAL-c383t-fc62ab4cddccb7037a4198104487c028c53b59297bde03801a6dd660b85fbe033
ISSN 2005-3711
IngestDate Fri May 02 05:43:39 EDT 2025
Thu Aug 21 18:26:53 EDT 2025
Thu Mar 27 21:18:16 EDT 2025
Mon May 12 02:38:37 EDT 2025
Mon Aug 11 02:42:38 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Rhabdoid tumor predisposition syndrome
Epigenomics
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c383t-fc62ab4cddccb7037a4198104487c028c53b59297bde03801a6dd660b85fbe033
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-9603-5843
0000-0001-7157-2119
OpenAccessLink http://dx.doi.org/10.3340/jkns.2025.0014
PMID 40143702
PQID 3181818819
PQPubID 23479
PageCount 10
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_10707757
pubmedcentral_primary_oai_pubmedcentral_nih_gov_12062526
proquest_miscellaneous_3181818819
pubmed_primary_40143702
crossref_primary_10_3340_jkns_2025_0014
PublicationCentury 2000
PublicationDate 2025-05-01
PublicationDateYYYYMMDD 2025-05-01
PublicationDate_xml – month: 05
  year: 2025
  text: 2025-05-01
  day: 01
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Journal of Korean Neurosurgical Society
PublicationTitleAlternate J Korean Neurosurg Soc
PublicationYear 2025
Publisher Korean Neurosurgical Society
대한신경외과학회
Publisher_xml – name: Korean Neurosurgical Society
– name: 대한신경외과학회
References ref13
ref56
ref15
ref14
Nemes (ref37) 1993
ref53
ref11
ref55
ref54
Lorca (ref35) 2024
ref17
ref16
ref18
ref51
ref50
ref46
ref45
Biegel (ref5) 1999
ref48
ref47
ref42
ref41
ref44
Bartelheim (ref3) 2016
ref43
ref49
Kohashi (ref31) 2017
ref8
ref7
ref9
ref4
ref6
ref40
ref34
ref36
ref30
ref33
ref32
ref2
Johann (ref29) 2016
ref1
ref39
ref38
Chi (ref10) 2009
Furtwängler (ref19) 2018
ref24
ref23
ref26
ref25
ref20
ref22
Torchia (ref52) 2015
ref21
ref28
ref27
Del Baldo (ref12) 2021
References_xml – ident: ref23
  doi: 10.1038/s41467-020-18070-y
– start-page: 586288
  volume-title: Rhabdoid tumor predisposition syndrome: from clinical suspicion to general management
  year: 2021
  ident: ref12
– ident: ref42
  doi: 10.1093/neuonc/noy111
– ident: ref47
  doi: 10.1053/j.semdp.2020.05.005
– start-page: e240015
  volume-title: Malignant rhabdoid tumor and related pediatric tumors: multimodality imaging review with pathologic correlation
  year: 2024
  ident: ref35
– ident: ref11
  doi: 10.1016/j.celrep.2019.10.013
– ident: ref50
  doi: 10.2350/14-07-1531-misc.1
– ident: ref4
  doi: 10.1016/j.gore.2015.02.002
– ident: ref25
  doi: 10.1093/neuonc/noz235
– start-page: 569
  volume-title: Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis
  year: 2015
  ident: ref52
– ident: ref39
  doi: 10.1080/14728222.2018.1451839
– start-page: e26746
  volume-title: High-dose treatment for malignant rhabdoid tumor of the kidney: no evidence for improved survival-the Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) experience
  year: 2018
  ident: ref19
– ident: ref44
  doi: 10.1177/1093526617749671
– ident: ref1
  doi: 10.1016/j.wneu.2017.11.158
– ident: ref2
  doi: 10.1002/pbc.30979
– ident: ref43
  doi: 10.1111/j.1440-1827.2006.01962.x
– ident: ref51
  doi: 10.1007/s00431-010-1377-2
– ident: ref45
  doi: 10.1007/s00401-018-1814-2
– ident: ref20
  doi: 10.1093/noajnl/vdae158
– ident: ref49
  doi: 10.1086/302639
– ident: ref33
  doi: 10.1016/j.bcp.2023.115727
– ident: ref36
  doi: 10.1038/ng.3958
– ident: ref13
  doi: 10.1158/1078-0432.ccr-17-0834
– ident: ref53
  doi: 10.1002/pbc.22922
– ident: ref7
  doi: 10.1016/s1470-2045(13)70088-3
– year: 1993
  ident: ref37
– ident: ref8
  doi: 10.1053/j.semdp.2021.03.003
– ident: ref22
  doi: 10.1007/s10689-015-9836-6
– ident: ref54
  doi: 10.1002/pbc.25093
– ident: ref15
  doi: 10.1055/s-0036-1579756
– start-page: 379
  volume-title: Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes
  year: 2016
  ident: ref29
– ident: ref32
  doi: 10.1002/pbc.24793
– ident: ref21
  doi: 10.1615/critrevoncog.2015013566
– ident: ref38
  doi: 10.1016/j.ejca.2020.10.004
– start-page: 547
  volume-title: Oncogenic roles of SMARCB1/INI1 and its deficient tumors
  year: 2017
  ident: ref31
– ident: ref17
  doi: 10.1093/neuonc/noz244
– ident: ref30
  doi: 10.1038/ng.2628
– ident: ref9
  doi: 10.1634/theoncologist.2018-0416
– ident: ref46
  doi: 10.1200/jco.19.01776
– ident: ref56
  doi: 10.1038/ng.3746
– ident: ref28
  doi: 10.1155/2013/315170
– start-page: 1765
  volume-title: Improved 6-year overall survival in AT/RT - results of the registry study Rhabdoid 2007
  year: 2016
  ident: ref3
– ident: ref27
  doi: 10.1038/s41431-018-0143-1
– ident: ref55
  doi: 10.1038/28212
– ident: ref48
  doi: 10.1016/j.ajhg.2010.01.013
– start-page: 385
  volume-title: Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor
  year: 2009
  ident: ref10
– ident: ref26
  doi: 10.1007/s00401-020-02250-7
– ident: ref14
  doi: 10.1002/pbc.22831
– ident: ref24
  doi: 10.1097/pas.0b013e3182196a39
– ident: ref40
  doi: 10.3390/cancers14092185
– ident: ref18
  doi: 10.1007/s10689-021-00229-1
– ident: ref41
  doi: 10.2147/cmar.s289544
– ident: ref16
  doi: 10.1158/1078-0432.ccr-17-0595
– start-page: 74
  volume-title: Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors
  year: 1999
  ident: ref5
– ident: ref6
  doi: 10.1158/1078-0432.ccr-10-1795
– ident: ref34
  doi: 10.1016/j.ccell.2019.10.008
SSID ssj0063085
Score 2.34716
Snippet Rhabdoid tumor predisposition syndrome (RTPS) is a rare autosomal dominant disorder characterized by an increased risk of developing malignant rhabdoid tumors...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 311
SubjectTerms Review
신경외과학
Title Rhabdoid Tumor Predisposition Syndrome : A Comprehensive Review of Genetics, Clinical Manifestations, and Management
URI https://www.ncbi.nlm.nih.gov/pubmed/40143702
https://www.proquest.com/docview/3181818819
https://pubmed.ncbi.nlm.nih.gov/PMC12062526
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003197979
Volume 68
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX 대한신경외과학회지, 2025, 68(3), , pp.311-320
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLe6ceGCQHyVj8kIJA5dILETJ-E2TaAyBEKjk3aL4o_QUi2Z0uTCkb-cZztOmq6HgSqlrVvHTd6vz8_27_2M0JuUyDSmknlECN8LQwF-kJPUU0kSMclyXymj9vmNzS_Cs8vocjL5s8Vaahv-Tvzem1fyP1aFMrCrzpL9B8v2J4UCeA32hSNYGI63svH5Mufgk-Rs0V5VtaZTyFVPw5r96MQIZi77_Oq6VsuOsH7ep6xo4emmowudujzJr7nmvGzsOv3GUTx3uDI3Y9ovVa1n9o3ix6atrVftiKHDar-B4CJXy2rgAHw3mwvPzlazuSvt5iJINDD_rMsyuqY07tyn6lyqVixN7C4vzueyZAtbdMuBUlfXvjOJcjfcPKWh5kX-WpdacJ3oWTGbiTrW097p53r2IYx79BkyXT_T9TWxLzxAd0gcm6V-M-Nje3NGfbOta39lVvhT138_bn8U2ByUdbFvzLJLvd2KZRb30b3OYPjEIuoBmqjyIWocmrBBEx6jCTs04Q_4BI-whC2WcFVgh6Vj7JCEx0g6xoAjPODoEbr49HFxOve6PTk8QRPaeIVgJOehkFIIDr1FnIdBmsCYHga-AmJVEVEeQcgdc6l8CuFPzqRkzOdJVHAooY_RYVmV6inCIhUJj6QsZB6EkigYqRQRV1GgglRwRaborbuh2bWVXsn2m26KXsP9ztZilWm1dP38s8rWdQZjws9QJ9Y6j_EUvXL2yMCH6oWxvFRVu8mgX9MPCI6n6Im1T99iqAUwYx9-TTKyXP8F3eL4k3K1NDrtAfEZiQh7dusLeY7uDn-rF-iwqVv1EoLehh-ZyaIjg82_nOWxNw
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rhabdoid+Tumor+Predisposition+Syndrome+%3A+A+Comprehensive+Review+of+Genetics%2C+Clinical+Manifestations%2C+and+Management&rft.jtitle=Journal+of+Korean+Neurosurgical+Society&rft.au=Kim%2C+Taehoon&rft.au=Phi%2C+Ji+Hoon&rft.date=2025-05-01&rft.issn=2005-3711&rft.eissn=1598-7876&rft.volume=68&rft.issue=3&rft.spage=311&rft.epage=320&rft_id=info:doi/10.3340%2Fjkns.2025.0014&rft.externalDBID=n%2Fa&rft.externalDocID=10_3340_jkns_2025_0014
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2005-3711&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2005-3711&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2005-3711&client=summon